Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NACT for Organ Preservation in Oral Tongue SCC
NCT02985255Phase 2Unknown
- Sponsor
- Healthcare Global Enterprises
- Start
- Apr 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in Squamous Cell Carcinoma of the Oral Tongue (SCCOT), sponsored by Healthcare Global Enterprises. Primary endpoint: Tongue Preservation Rate at 7 months. Status: unknown.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
Squamous Cell Carcinoma of the Oral Tongue (SCCOT)
Beyond the preview
Go deeper on NCT02985255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985255.